Extracorporeal membrane oxygenation during the first three waves of the coronavirus disease 2019 pandemic: A retrospective single-center registry study.
COVID-19
extracorporeal membrane oxygenation
survival
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
13
03
2022
received:
23
12
2021
accepted:
11
04
2022
pubmed:
23
4
2022
medline:
25
8
2022
entrez:
22
4
2022
Statut:
ppublish
Résumé
Despite increasing knowledge about the optimal treatment for patients with severe COVID-19, data from different cohorts suggested that survival of patients treated with ECMO seemed to decline over the course of the pandemic. In this non-interventional retrospective single-center registry study we analyzed all consecutive patients tested positive for SARS-CoV-2 infection and supported with VV ECMO in our center during the first three waves of the pandemic. From March 2020 through June 2021, 59 patients have been included. Overall 90-day survival was 32%. Besides changes in drug treatment for COVID-19 and a lower PaO VV ECMO has shown to be a feasible and safe support option for patients with severe respiratory failure due to COVID-19. The results from this single-center study confirm findings from other cohorts showing declining survival rates of patients treated with VV ECMO during the COVID-19 pandemic, however, the specific reasons for this finding remain unclear.
Sections du résumé
BACKGROUND
BACKGROUND
Despite increasing knowledge about the optimal treatment for patients with severe COVID-19, data from different cohorts suggested that survival of patients treated with ECMO seemed to decline over the course of the pandemic.
METHODS
METHODS
In this non-interventional retrospective single-center registry study we analyzed all consecutive patients tested positive for SARS-CoV-2 infection and supported with VV ECMO in our center during the first three waves of the pandemic. From March 2020 through June 2021, 59 patients have been included.
RESULTS
RESULTS
Overall 90-day survival was 32%. Besides changes in drug treatment for COVID-19 and a lower PaO
CONCLUSIONS
CONCLUSIONS
VV ECMO has shown to be a feasible and safe support option for patients with severe respiratory failure due to COVID-19. The results from this single-center study confirm findings from other cohorts showing declining survival rates of patients treated with VV ECMO during the COVID-19 pandemic, however, the specific reasons for this finding remain unclear.
Identifiants
pubmed: 35451145
doi: 10.1111/aor.14270
pmc: PMC9111358
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1876-1885Informations de copyright
© 2022 The Authors. Artificial Organs published by International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.
Références
Lancet Respir Med. 2020 Apr;8(4):e24
pubmed: 32178774
JAMA. 2019 Aug 13;322(6):557-568
pubmed: 31408142
Am J Respir Crit Care Med. 2021 Oct 15;204(8):991-994
pubmed: 34283685
Lancet Respir Med. 2021 Aug;9(8):851-862
pubmed: 33887246
N Engl J Med. 2018 May 24;378(21):1965-1975
pubmed: 29791822
Crit Care. 2022 Jan 10;26(1):17
pubmed: 35012622
Chest. 2022 Apr;161(4):989-998
pubmed: 34655568
Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):248-252
pubmed: 32347745
Lancet Respir Med. 2019 Feb;7(2):108-110
pubmed: 30642778
ASAIO J. 2020 Jul;66(7):707-721
pubmed: 32604322
Artif Organs. 2022 Sep;46(9):1876-1885
pubmed: 35451145
ASAIO J. 2021 Jun 1;67(6):601-610
pubmed: 33965970
Lancet Respir Med. 2020 Nov;8(11):1121-1131
pubmed: 32798468
Lancet. 2021 Oct 2;398(10307):1230-1238
pubmed: 34599878
ASAIO J. 2021 May 1;67(5):485-495
pubmed: 33657573
Lancet Respir Med. 2021 Aug;9(8):e72-e74
pubmed: 34242580
BMC Anesthesiol. 2017 Jan 26;17(1):12
pubmed: 28122489
Intensive Care Med. 2013 Oct;39(10):1704-13
pubmed: 23907497
Am J Respir Crit Care Med. 2021 Oct 15;204(8):994-997
pubmed: 34375170
Intensive Care Med. 2020 Nov;46(11):2048-2057
pubmed: 33021684
Lancet Respir Med. 2021 Apr;9(4):326-328
pubmed: 33798457
Crit Care. 2019 Nov 27;23(1):374
pubmed: 31775846
Lancet Respir Med. 2019 Feb;7(2):163-172
pubmed: 30642776
Am J Respir Crit Care Med. 2014 Jun 1;189(11):1374-82
pubmed: 24693864
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Ann Intensive Care. 2022 Jan 13;12(1):6
pubmed: 35024972
Lancet. 2020 Oct 10;396(10257):1071-1078
pubmed: 32987008
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
ASAIO J. 2020 Jun;66(6):588-598
pubmed: 32358232
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Am J Respir Crit Care Med. 2015 Apr 15;191(8):894-901
pubmed: 25695688
Crit Care. 2021 Oct 9;25(1):355
pubmed: 34627350
Crit Care. 2021 Nov 29;25(1):413
pubmed: 34844657
Lancet Respir Med. 2021 Aug;9(8):e80-e81
pubmed: 34146489
Lancet Respir Med. 2021 Apr;9(4):430-434
pubmed: 33450202
Crit Care. 2021 Jun 14;25(1):211
pubmed: 34127027
JAMA. 2018 Dec 4;320(21):2251-2259
pubmed: 30347031
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Crit Care. 2021 Mar 1;25(1):90
pubmed: 33648538
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
J Crit Care. 2020 Aug;58:27-28
pubmed: 32279018